Join this Featured Workgroup!
Elite Investors

This group is for elite investors and traders that are dedicated to participating in an active community that wants to learn from each other, share their research, and work together to do deep analysis of securities. The moderator of this group taught securities analysis at UCLA and is dedicated to helping other investors improve their abilities.

In this private group, membership is restricted and regular contributions are required. Any member not contributing on a regular basis will be removed to make room for a new member.

In your application messsage, please share your background and what you can contribute to the group.



Company Overview and News

0
KZR / Kezar Life Sciences, Inc. / FMR LLC / Fidelity - null (Passive Investment)

2018-08-10 sec.gov
SCHEDULE 13G Amendment No. 0 KEZAR LIFE SCIENCES INC COMMON STOCK Cusip #49372L100 Check the appropriate box to designate the rule pursuant to which this Schedule is filed: [x] Rule 13d-1(b) [ ] Rule 13d-1(c) [ ] Rule 13d-1(d) Cusip #49372L100 Item 1: Reporting Person - FMR LLC Item 2: (a) [ ] (b) [ ] Item 4: Delaware Item 5: 0 Item 6: 0 Item 7: 2,173,956 Item 8: 0 Item 9: 2,173,956 Item 11: 11.398% Item 12: HC Cusip #49372L100 Item 1: Reporting Person - Abigail P.
KZR

0
KZR / Kezar Life Sciences, Inc. / FMR LLC / Fidelity - null (Passive Investment)

2018-08-10 sec.gov
SCHEDULE 13G Amendment No. 0 KEZAR LIFE SCIENCES INC COMMON STOCK Cusip #49372L100 Check the appropriate box to designate the rule pursuant to which this Schedule is filed: [x] Rule 13d-1(b) [ ] Rule 13d-1(c) [ ] Rule 13d-1(d) Cusip #49372L100 Item 1: Reporting Person - FMR LLC Item 2: (a) [ ] (b) [ ] Item 4: Delaware Item 5: 0 Item 6: 0 Item 7: 2,173,956 Item 8: 0 Item 9: 2,173,956 Item 11: 11.398% Item 12: HC Cusip #49372L100 Item 1: Reporting Person - Abigail P.
KZR

0
KZR / Kezar Life Sciences, Inc. 10-Q (Quarterly Report)

2018-08-09 sec.gov
kzr-10q_20180630.htm 75
KZR

0
KZR / Kezar Life Sciences, Inc. 8-K (Current Report)

2018-08-09 sec.gov
kzr-8k_20180809.htm UNITED STATES
KZR

0
Vaccinex IPO: Tempting Market Opportunity, But Overvalued

2018-08-09 seekingalpha
Vaccinex, Inc. is a biotechnology company focused on the development of biotherapeutics to treat cancer, neurodegenerative diseases, and autoimmune disorders.
MRK MEDX KZR

0
KZR / Kezar Life Sciences, Inc. null

2018-07-20 sec.gov
begin 644 filename1.pdf M)5!$1BTQ+C4-)>+CS],-"C$Q(# @;V)J#3P\+TQI;F5A
KZR

0
KZR / Kezar Life Sciences, Inc. null

2018-07-20 sec.gov
DRSLTR By EDGAR and courier Jaime L. Chase +1 202 728 7096 [email protected] May 4, 2018
KZR

0
KZR / Kezar Life Sciences, Inc. null

2018-07-20 sec.gov
begin 644 filename1.pdf M)5!$1BTQ+C4-)>+CS],-"[email protected],"!O8FH-/#PO3&EN96%R:7IE9" [email protected],S,T M,C4O3R Q,2]%(#(X,3 [email protected],B]4(#,S,3([email protected]@6R [email protected],30Y73X^#65N M9&]B:@[email protected](" @(" @(" @(" @(" @(" @#0HQ-B P(&]B:@T\/"]$96-O9&50 M87)M7!E+UA2968O5ULQ(#(@,5T^/G-T('[email protected]&)D:&&2 E#(Q,_QEW_P<(, "[email protected][email protected] M#0IE;F1S=')E86T-96YD;V)J#7-T87)T>')[email protected]*, T*)25%3T8-"B @(" @ M(" @#0HQ.2 P(&]B:@T\/"]&:6QT97(O1FQA=&5$96-O9&4O22 X,R],96YG [email protected]@-S O4R T.
KZR

0
KZR / Kezar Life Sciences, Inc. null

2018-07-20 sec.gov
CORRESP Jaime L. Chase
KZR

0
KZR / Kezar Life Sciences, Inc. null

2018-07-20 sec.gov
CORRESP Jaime L. Chase
KZR

0
KZR / Kezar Life Sciences, Inc. null

2018-07-20 sec.gov
begin 644 filename1.pdf M)5!$1BTQ+C4*)>+CS],*,2 P(&]B:@H\/"]4>7!E+UA/8FIE8W0O0V]L;W)3 M<&%C92]$979I8V5'
KZR

0
KZR / Kezar Life Sciences, Inc. null

2018-07-20 sec.gov
CORRESP Jaime L. Chase
KZR

0
KZR / Kezar Life Sciences, Inc. null

2018-07-20 sec.gov
CORRESP June 18, 2018 VIA EDGAR Securities and Exchange Commission Division of Corporation Finance 100 F Street, N.E.
KZR

0
KZR / Kezar Life Sciences, Inc. null

2018-07-20 sec.gov
CORRESP KEZAR LIFE SCIENCES, INC. 4000 Shoreline Court, Suite 300 South San Francisco, California 94080 June 18, 2018 VIA EDGAR
KZR

0
Cash Rich Replimune: Bain Capital Is Inside, But The Research Seems At An Early Stage

2018-07-19 seekingalpha
Replimune is currently conducting a Phase 1/2 clinical trial to treat cancer. Initiation of Phase 2 clinical trial of RP1 with Regeneron is expected in the first half of 2019.
REGN AMGN AUTL KZR BMY

Related Articles

RNVA: Rennova Health Analysis and Research Report

4h - Asif

Business overview Rennova Health, Inc. (together with its subsidiaries, “Rennova”, “we” or the “Company”) is a provider of an expanding group of health care services for healthcare providers, patients and individuals. Beginning in 2018, the Company intends to focus on and operate two synergistic divisions: 1) Clinical diagnostics through its clinical laboratories; and 2) Hospital operations through its Big South Fork Medical Center, which opened on August 8, 2017, and a hospital in Jamestown Tennessee, including a doctor’s practice, the assets of which the company expect to acquire in the second quarter of 2018, pursuant to the terms of a definitive asset purchase agreement that the company entered into on January 31, 2018, as more fully discussed below. The company believe that its approach will produce a more sustainable business model and the capture of multiple revenue streams from medical providers, patients and hospital services. Management determined that because Big So...

BLDP: Ballard Power Systems Analysis and Research Report

2018-08-13 - Asif

Core Business At Ballard, Ballard Power Systems is building a clean energy growth company. Ballard Power Systems is recognized as a world leader in proton exchange membrane (“PEM”) fuel cell power system development and commercialization. The company's principal business is the design, development, manufacture, sale and service of PEM fuel cell products for a variety of applications, focusing on its power product markets of Heavy-Duty Motive (consisting of bus, truck, rail and marine applications), Portable Power, Material Handling and Backup Power, as well as the delivery of Technology Solutions, including engineering services, technology transfer, and the license and sale of its extensive intellectual property portfolio and fundamental knowledge for a variety of fuel cell applications. A fuel cell is an environmentally clean electrochemical device that combines hydrogen fuel with oxygen (from the air) to produce electricity. The hydrogen fuel can be obtained from natural g...

MARA: Marathon Patent Group Analysis and Research Report

2018-08-13 - Asif

Overview Marathon Patent Group was incorporated in the State of Nevada on February 23, 2010 under the name Verve Ventures, Inc. On December 7, 2011, the company changed its name to American Strategic Minerals Corporation and were engaged in exploration and potential development of uranium and vanadium minerals business. In June 2012, the company discontinued its minerals business and began to invest in real estate properties in Southern California. In October 2012, the company discontinued its real estate business when its former CEO joined the firm and the company commenced its IP licensing operations, at which time the Company’s name was changed to Marathon Patent Group, Inc. On November 1, 2017, the company entered into a merger agreement with Global Bit Ventures, Inc. (“GBV”), which is focused on mining digital assets. Marathon Patent Group has since purchased its cryptocurrency mining machines and established a data center in Canada to mine digital assets. Following the me...

CUSIP: 49372L100